Cue Biopharma
89 hedge funds and large institutions have $216M invested in Cue Biopharma in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 10 closing their positions.
Holders
89
Holders Change
–
Holders Change %
0%
% of All Funds
1.55%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
29
Reduced
32
Closed
10
Calls
$814K
Puts
$1.68M
Net Calls
-$865K
Net Calls Change
+$1.46M
Top Buyers
| 1 |
WP
1
Woodline Partners
San Francisco,
California
|
$7.77M |
| 2 |
6CM
2
683 Capital Management
New York
|
$8.2M |
| 3 |
3
Millennium Management
New York
|
$2.67M |
| 4 |
4
Morgan Stanley
New York
|
$4.98M |
| 5 |
BL
5
Bleichroeder LP
New York
|
$2.04M |
Top Sellers
| 1 |
CA
1
Corriente Advisors
Fort Worth,
Texas
|
$17.3M |
| 2 |
2
Goldman Sachs
New York
|
$4.6M |
| 3 |
3
Two Sigma Investments
New York
|
$2.34M |
| 4 |
SMH
4
Sanders Morris Harris
Houston,
Texas
|
$2.77M |
| 5 |
5
BlackRock
New York
|
$25M |
